Accelerating Medicines Partnership® Program – Rheumatoid Arthritis, Systemic Lupus Erythematosus

Enhancing the biological understanding of complex autoimmune disorders to enable better treatments for patients

The Problem
Autoimmune disorders such as Rheumatoid Arthritis and Systemic Lupus Erythematosus are biologically complex, and better understanding of the biological processes that cause these conditions is needed to treat them effectively.
The Solution
AMP® RA/SLE is investigating the biological processes that underly autoimmune disorders such as Rheumatoid Arthritis and Systemic Lupus Erythematosus to facilitate the development of more effective treatments.


The FNIH’s Accelerating Medicines Partnership® (AMP®) program includes an initiative focused on Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) & Related Autoimmune Disorders. AMP is a multi-sector, pre-competitive partnership among government, industry and nonprofit organizations that aims to harness collective capabilities, scale and resources to improve current efforts to develop new therapies for complex, heterogeneous diseases. The AMP RA/SLE Program focuses on molecular analyses of gene expression and signaling in specific subsets of immune cells and resident tissue cells, in RA patients’ synovium and blood and in lupus patients’ kidney biopsy, skin and blood. AMP RA/SLE uses novel technologies to molecularly deconstruct and analyze these highly refined relevant cell subsets or single cells, in order to understand the mechanisms of disease. 

In recent years, treatment of autoimmune diseases has benefited from the ability of therapies to target specific immune cells and inflammatory mediators. However, the clinical benefits achieved so far have been limited. For example, despite an increase in the number of available biotherapies that reduce RA disease activity, many patients respond poorly to all current therapeutics, and many patients who initially respond to a drug experience diminished responses over time, for unknown reasons. Moreover, no effective therapies exist for the most severe forms of SLE, including those affecting the central nervous system (CNS) or the kidneys (e.g., lupus nephritis). The collaborative AMP RA/SLE Program is working to transform the approach to defining the pathogenesis of autoimmune diseases, improve patient enrichment strategies to ensure the best use of existing therapies and enable the identification of potential new pathways or targets for RA/SLE drug development and intervention.

Click here to watch a video about the AMP RA/Lupus program from a patient perspective. 



Public-Sector Partners

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Private-Sector Partners

  • AbbVie* 
  • Arthritis Foundation*
  • Bristol-Myers Squibb Company*
  • GlaxoSmithKline*
  • Janssen Research and Development, LLC*
  • Lupus Foundation of America*
  • Lupus Research Alliance*
  • Merck & Co., Inc.*
  • Pfizer Inc*
  • Rheumatology Research Foundation*
  • Sanofi*
  • Takeda Pharmaceuticals International, Inc.*

*Provided financial or in-kind support for this program.

FNIH Contact

Results & Accomplishments

Data Access

  • Data from Phase 1 of the research plan was made publicly available on November 1, 2017. Genotype and Phenotype data are available upon authorized request through dbGaP, accession phs001457. v1. p1. Read more
  • Additional datasets can be accessed through ImmPort, accession: SDY998, SDY999. Read more
  • Learn about the AMP projects focused on Alzheimer’s disease, type 2 diabetes and Parkinson's disease.
  • Read a program overview on the NIAMS website here.
  • AMP RA/SLE has led to nineteen peer-reviewed scientific journal articles.

Accelerating Medicines Partnership® Program - Alzheimer's Disease

Accelerating Medicines Partnership® Program - Common Metabolic Diseases

Accelerating Medicines Partnership® Program Bespoke Gene Therapy

ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.